文献速递骨肿瘤

新辅助化疗后延迟手术:对所有非转移性高级别骨盆骨肉瘤患者都必要吗

Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

本回顾性研究纳入2000年至2015年本中心112例非转移性高级别原发性骨盆骨肉瘤患者中的89例,比较新辅助化疗后延迟手术组(56例)与即刻手术加辅助化疗组(33例)的生存与局部复发情况;两组5年总生存率、保肢情况及5年无局部复发生存率均无差异,作者认为化疗时机应基于生存以外的原因决定,并需前瞻性试验确认。

要点

  • 新辅助化疗后延迟手术组与即刻手术加辅助化疗组5年总生存率无差异(43% vs 40%,p=0.709)。
  • 两组5年无局部复发生存率无差异(68% vs 67%,p=0.595)。
  • 新辅助化疗组56例中仅4例达到90%坏死,作者认为该阈值是否适用于骨盆骨肉瘤尚需确认。

核心结论

  • 作者结论:在非转移性高级别骨盆骨肉瘤患者中,术前化疗相较即刻手术未见生存优势,化疗时机的决定应基于生存以外的原因,并需前瞻性试验确认该结论。

研究设计与样本

  • 回顾性研究,2000年至2015年本中心治疗112例非转移性高级别原发性骨盆骨肉瘤患者,其中93例行肿瘤切除加化疗,4例(4%)在24个月前失访但未知死亡,余89例纳入分析。
  • 按手术与化疗时机分为两组:新辅助化疗后延迟手术加辅助化疗组56例(平均随访61个月,范围27-137个月),即刻手术加辅助化疗组33例(平均随访77个月,范围25-193个月)。
  • 两组化疗总时长与强度相似;采用Kaplan-Meier法、单因素log-rank检验及多因素Cox分析比较总生存与局部复发。
  • 证据等级:Level III,治疗性研究。

主要发现

  • 全部患者5年总生存率为42%(95% CI,33-52);新辅助化疗组为43%(95% CI,30-56),即刻手术组为40%(95% CI,25-55),p=0.709。
  • 保肢情况:新辅助化疗组56例中5例(89%)与即刻手术组33例中3例(91%)比较,p=0.557。
  • 5年无局部复发生存率为67%(95% CI,59-76),两组间无差异(68%;95% CI,57-78% 对比 67%;95% CI,52-81;p=0.595)。
  • 新辅助化疗组肿瘤坏死超过90%的患者与其余患者间生存无差异,但新辅助化疗组56例中仅4例达到90%坏死。
  • 新辅助化疗组骶骨浸润比例更高,性别、年龄及肿瘤大小等其余因素两组间均衡。

关键数值与推荐

  • 原文未报告指南或共识推荐条款。

临床怎么用

  • 本研究中心的做法是:患者在本中心接受活检时,一般使用新辅助治疗加延迟手术及辅助化疗;患者最初拒绝化疗或存在严重疼痛、行走功能差时,通常采用即刻手术加辅助化疗。
  • 作者认为化疗时机的决定应基于生存以外的原因,并需前瞻性试验确认该结论。

局限性

  • 原文结论指出需前瞻性试验确认该结论。
  • 新辅助化疗组56例中仅4例达到90%坏死,作者据此认为该阈值能否区分骨盆骨肉瘤的应答者与非应答者尚不能确定。
  • 原文在保肢比较处写明「With the numbers available」,即按现有例数未发现差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy is the most-frequently employed strategy for patients with high-grade osteosarcoma. However, the contribution of neoadjuvant chemotherapy compared with postoperative adjuvant chemotherapy has not been tested rigorously in patients with nonmetastatic high-grade pelvic osteosarcoma. QUESTIONS/PURPOSES: (1) Does neoadjuvant chemotherapy followed by delayed surgery offer a survival benefit to patients with nonmetastatic high-grade pelvic osteosarcoma compared with immediate surgery and adjuvant chemotherapy? (2) Is the timing of chemotherapy and surgery associated with a difference in the survivorship free from local recurrence and the risk of complications? (3) Is the threshold of 90% necrosis after neoadjuvant chemotherapy appropriate to distinguish responders from nonresponders in patients with pelvic osteosarcoma? METHODS: Between 2000 and 2015, our center treated 112 patients with nonmetastatic high-grade primary pelvic osteosarcoma, of whom 93 underwent tumor resection with chemotherapy. Four patients (4%) were lost to followup before 24 months but were not known to have died; the remaining 89 patients were included in this retrospective study. Based on the timing of surgery and chemotherapy, patients were analyzed in two groups: (1) neoadjuvant chemotherapy followed by delayed surgery and adjuvant chemotherapy (n = 56; mean followup of 61 months, range 27-137 months), and (2) immediate surgery followed by adjuvant chemotherapy (n = 33; mean followup of 77 months, range 25-193 months). The total duration and intensity of chemotherapy was similar in both groups. During the period in question, we generally used neoadjuvant therapy followed by delayed surgery and adjuvant chemotherapy when patients received their biopsies in our center. We typically used immediate surgery with adjuvant chemotherapy when patients initially refused chemotherapy or when they had severe pain or poor walking function. Patients in the neoadjuvant chemotherapy group had a higher proportion of sacral infiltration; other factors such as sex, age and tumor size were well balanced between groups. We compared overall survival and local recurrence-free survival rates between the two groups. We completed univariate log-rank tests and multivariate Cox analyses in all patients to identify factors associated with survival and local recurrence using the Kaplan-Meier method. RESULTS: No survival benefit was found in the patients treated with neoadjuvant chemotherapy followed by delayed surgery compared with the group treated with immediate surgery and adjuvant chemotherapy. At 5 years, the overall survival (OS) was 42% (95% CI, 33-52) for all patients in this study, 43% (95% CI, 30-56) for the neoadjuvant group, and 40% (95% CI, 25-55) for the immediate surgery group; p = 0.709. With the numbers available, there was no difference in the likelihood of successful limb salvage (five of 56 patients [89%] in the neoadjuvant chemotherapy group versus three of 33 patients [91%] in the immediate surgery group; p = 0.557). The 5-year local recurrence-free survival was 67% (95% CI, 59-76) with no difference between the two groups (68%; 95% CI, 57-78% versus 67%; 95% CI, 52-81; p = 0.595). With the numbers available, there was no difference in survival between patients whose tumors demonstrated more than 90% necrosis; however, only four of 56 patients in the neoadjuvant chemotherapy group demonstrated 90% necrosis. CONCLUSIONS: We found no survival advantage with chemotherapy before surgery compared with immediate surgery in patients with nonmetastatic high-grade pelvic osteosarcoma. The decision on chemotherapy timing should be made for reasons other than survival. A prospective trial is needed to confirm this conclusion. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Xu J, Xie L, Guo W, et al. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma? Clin Orthop Relat Res. 2018. PMID: 29912746. doi:10.1097/CORR.0000000000000387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。